← Oncology Approval Tracker

FDA DECISION ·

Elrexfio

elranatamab-bcmm · Pfizer

Accelerated approvalNew therapyMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with relapsed or refractory multiple myeloma after four or more lines that included a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 antibody.

LAMPGEN ANALYSIS

Why it matters

This accelerated approval added another BCMA-directed bispecific option after extensive prior therapy.

What research teams should watch

Verify line count and drug-class exposure, then plan step-up dosing and cytokine release syndrome monitoring.

PRIMARY RECORDS

Sources